Skip to main content
Journal cover image

Morbidity, Mortality, and Therapeutics in Combined Immunodeficiency: Data From the USIDNET Registry.

Publication ,  Journal Article
Durkee-Shock, J; Zhang, A; Liang, H; Wright, H; Magnusson, J; Garabedian, E; Marsh, RA; Sullivan, KE; Keller, MD; USIDNET Consortium,
Published in: J Allergy Clin Immunol Pract
May 2022

BACKGROUND: Optimal management of patients with combined immunodeficiency, especially pertaining to hematopoietic stem cell transplantation (HSCT), remains unclear. OBJECTIVE: To identify factors influencing HSCT and mortality in the population with combined immunodeficiency in North America. METHODS: We identified 337 participants in the United States Immunodeficiency Network database with diverse forms of combined immunodeficiency and their characteristics, including demographic characteristics, laboratory values, infectious history, comorbidities, and treatment strategies. Univariate analysis was performed using logistic regression, whereas multivariate analysis was performed using multiple Cox proportional hazards. RESULTS: On univariate analysis, disseminated invasive viral infections and variants in STAT3, GATA2, and, DOCK8 were associated with increased odds of HSCT. Mucocutaneous fungal infections and variants in STAT3 were associated with increased odds of survival, whereas disseminated/invasive fungal infections, disseminated/invasive viral infections, and parasitic infections were associated with decreased odds of survival. On multiple variable Cox proportional hazards analysis, variants in ZAP70, nonspecific bacterial, and disseminated/invasive viral infections were associated with increased hazards of transplantation, whereas variants in multiple genes (RMRP, NEMO, DOCK8, CD40L, and CARD9), disseminated/invasive viral infections, autoimmune disease, and higher absolute lymphocyte count were associated with increased hazards of death. Importantly, demographic characteristics, basic lymphocyte subset counts, and absence of genetic diagnosis were not associated with HSCT or mortality. CONCLUSIONS: We determined that specific genetic diagnoses and infection burden impacts the decision to undergo HSCT in this cohort. In addition, certain genetic diagnoses and invasive viral infections carry an increased risk of mortality.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Allergy Clin Immunol Pract

DOI

EISSN

2213-2201

Publication Date

May 2022

Volume

10

Issue

5

Start / End Page

1334 / 1341.e6

Location

United States

Related Subject Headings

  • Registries
  • Primary Immunodeficiency Diseases
  • Morbidity
  • Lymphocyte Count
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Guanine Nucleotide Exchange Factors
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Durkee-Shock, J., Zhang, A., Liang, H., Wright, H., Magnusson, J., Garabedian, E., … USIDNET Consortium, . (2022). Morbidity, Mortality, and Therapeutics in Combined Immunodeficiency: Data From the USIDNET Registry. J Allergy Clin Immunol Pract, 10(5), 1334-1341.e6. https://doi.org/10.1016/j.jaip.2022.01.042
Durkee-Shock, Jessica, Anqing Zhang, Hua Liang, Hannah Wright, Julieann Magnusson, Elizabeth Garabedian, Rebecca A. Marsh, Kathleen E. Sullivan, Michael D. Keller, and Michael D. USIDNET Consortium. “Morbidity, Mortality, and Therapeutics in Combined Immunodeficiency: Data From the USIDNET Registry.J Allergy Clin Immunol Pract 10, no. 5 (May 2022): 1334-1341.e6. https://doi.org/10.1016/j.jaip.2022.01.042.
Durkee-Shock J, Zhang A, Liang H, Wright H, Magnusson J, Garabedian E, et al. Morbidity, Mortality, and Therapeutics in Combined Immunodeficiency: Data From the USIDNET Registry. J Allergy Clin Immunol Pract. 2022 May;10(5):1334-1341.e6.
Durkee-Shock, Jessica, et al. “Morbidity, Mortality, and Therapeutics in Combined Immunodeficiency: Data From the USIDNET Registry.J Allergy Clin Immunol Pract, vol. 10, no. 5, May 2022, pp. 1334-1341.e6. Pubmed, doi:10.1016/j.jaip.2022.01.042.
Durkee-Shock J, Zhang A, Liang H, Wright H, Magnusson J, Garabedian E, Marsh RA, Sullivan KE, Keller MD, USIDNET Consortium. Morbidity, Mortality, and Therapeutics in Combined Immunodeficiency: Data From the USIDNET Registry. J Allergy Clin Immunol Pract. 2022 May;10(5):1334-1341.e6.
Journal cover image

Published In

J Allergy Clin Immunol Pract

DOI

EISSN

2213-2201

Publication Date

May 2022

Volume

10

Issue

5

Start / End Page

1334 / 1341.e6

Location

United States

Related Subject Headings

  • Registries
  • Primary Immunodeficiency Diseases
  • Morbidity
  • Lymphocyte Count
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Guanine Nucleotide Exchange Factors
  • 3204 Immunology